Overall, these findings suggest an oncological potential of SMARCB1 as a prognosis biomarker for EGFR-TKI-based therapy responsiveness in lung cancer, uncovering its in vivo function as a tumor suppressor gene and a significant epigenetic actor in human lung cancer progression. This evidence concerns the gene SMARCB1 and neoplasm.